Gut microbiome in Parkinson's disease: New insights from meta-analysis

Toh, Tzi Shin; Chong, Chun Wie; Lim, Shen‐Yang; Bowman, Jeff S.; Cirstea, Mihai; Lin, Chin‐Hsien; Chen, Chieh‐Chang; Appel‐Cresswell, Silke; Finlay, B. Brett; Tan, Ai Huey

doi:10.1016/j.parkreldis.2021.11.017

Cited by 82 publications

(69 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found one Genus with the family Veillonellaceae , Megasphaera , to show significantly higher abundance in patients with diabetes and depression. This genus has been found to be associated with Parkinson’s disease [ 27 ] and with large-artery atherosclerotic ischemic stroke and transient ischemic attack [ 28 , 29 ] Megasphaera produces short chain fatty acids [ 30 ] which are often though of as beneficial; however, association of the genus with pathological conditions suggests that unknown factors that influence pathogenesis exist. Both groups with diabetes showed a higher abundance of Christensenellaceae , another Firmicutes bacterium, than the healthy control group.…”

Section: Discussionmentioning

confidence: 99%

Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study

et al. 2022

View full text Add to dashboard Cite

Background Individuals with type 1 diabetes and those with depression show differences in the composition of the gut microbiome from that of healthy people. However, these differences have not yet been studied in patients with both diseases. Therefore, we compared the gut microbiome of people with type 1 diabetes with or without depression with matched healthy controls. Methods A case-control study was conducted in 20 adults with type 1 diabetes (group A), 20 adults with type 1 diabetes and depression (group B), and 20 healthy adults (group C). Gut microbiota composition was determined by sequencing of the V3-V4 region of the bacterial 16S rDNA and alpha and beta diversity was compared between the groups. Results Groups A and B both showed higher alpha diversity than the healthy control group (P < 0.001) but alpha diversity did not differ significantly between groups A and B. Participants having type 1 diabetes with (P < 0.05) or without comorbid depression (P < 0.001) differed regarding beta diversity from healthy controls but not between each other. Group B (diabetes with depression) had significantly higher abundance of Megaspaera than groups A and C. Both diabetes groups had a higher abundance of Christensenellaceae, Succinivibrionaceae, and Rhodospirillaceae than the healthy group but similar between-group abundances. Conclusions While differences in alpha and beta diversity and in some bacterial taxa occurred only between participants with diabetes and healthy controls, specific characteristics regarding the abundance of Megasphaera were observed in people with diabetes and comorbid depression. In summary, the study findings indicate a possible involvement of bacterial groups in depression in people with diabetes. The results suggest replication studies in larger samples to verify these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…One meta-analysis of 15 case-control studies observed that Prevotellaceae, Lachnospiraceae, and Faecalibacterium were decreased significantly in patients with PD compared to healthy controls, while Ruminococcaceae, Bifidobacteriaceae, Christensenellaceae, and Verrucomicrobiaceae were enriched in patients with PD (41). Another recent meta-analysis of 10 relevant studies found an abundance of Megasphaera and Akkermansia, and reduced Roseburia in PD patients (42). To date, the most consistently shown PD-related changes of gut microbial composition include an increase in the relative abundances of Verrucomicrobiaceae and Akkermansia and a decrease in Prevotellaceae and Prevotella (38).…”

Section: Altered Gut Microbiota Characteristics In Pdmentioning

confidence: 99%

Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease

Zhu

Liu

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disease characterized by motor dysfunction. Growing evidence has demonstrated that gut dysbiosis is involved in the occurrence, development and progression of PD. Numerous clinical trials have identified the characteristics of the changed gut microbiota profiles, and preclinical studies in PD animal models have indicated that gut dysbiosis can influence the progression and onset of PD via increasing intestinal permeability, aggravating neuroinflammation, aggregating abnormal levels of α-synuclein fibrils, increasing oxidative stress, and decreasing neurotransmitter production. The gut microbiota can be considered promising diagnostic and therapeutic targets for PD, which can be regulated by probiotics, psychobiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, diet modifications, and Chinese medicine. This review summarizes the recent studies in PD-associated gut microbiota profiles and functions, the potential roles, and mechanisms of gut microbiota in PD, and gut microbiota-targeted interventions for PD. Deciphering the underlying roles and mechanisms of the PD-associated gut microbiota will help interpret the pathogenesis of PD from new perspectives and elucidate novel therapeutic strategies for PD.

show abstract

“…In contrast, MSA primarily affects the central nervous system, such as the brain and spinal cord, but not the enteric nervous system [ 19 ]. Recently, the relationship between the accumulation of α-synuclein and gut dysbiosis has been attracting increased attention [ 24 , 25 , 26 , 27 ]. Nishiwaki et al analyzed the gut microbiota of PD patients worldwide [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Constipation Symptoms in Multiple System Atrophy Using Rome Criteria and Their Impact on Personalized Medicine

Mishima

Fujioka

Kawazoe

et al. 2022

JPM

View full text Add to dashboard Cite

Constipation is one of the most common non-motor symptoms in multiple system atrophy (MSA); however, it has not been evaluated according to the standard diagnostic criteria for constipation in patients with MSA. We evaluated the characteristics of constipation in patients with MSA by using Rome criteria (Rome III), which has been validated and the widely used for gastrointestinal disorders. Fifty-one patients with MSA (29 female) were enrolled in the study. Based on the Rome III criteria, constipation was diagnosed in 29 patients (56.9%); irritable bowel syndrome was not detected. Thirty-seven patients (72.5%) were aware of their constipation. The most common constipation symptom was the sensation of anorectal obstruction (68.6%). Patients’ self-awareness of constipation was most strongly correlated to the sensation of incomplete evacuation (odds ratio: 7.377, 95% confidence interval: 1.402–38.817). The number of constipation-related symptoms was correlated with the total levodopa equivalent dose (p < 0.05). Rome criteria, which can detect various constipation symptoms, are useful for evaluating constipation in MSA, and these findings may greatly impact personalized medicine.

show abstract

Gut microbiome in Parkinson's disease: New insights from meta-analysis

Cited by 82 publications

References 40 publications

Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study

Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study

Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease

Constipation Symptoms in Multiple System Atrophy Using Rome Criteria and Their Impact on Personalized Medicine

Contact Info

Product

Resources

About